High-quality monoclonal antibodies to access any target, including GPCRs, ion channels, and transporters
The only service that delivers pan-reactive reagent mAbs that cross-react with multiple mammalian species, including rodent and NHP
Therapeutic-Quality Antibodies at a Fraction of the Cost
Leveraging Integral Molecular’s clinical-grade discovery platform to deliver therapeutic-quality antibodies at research-stage pricing—even for the most challenging targets, including multipass membrane proteins such as GPCRs, ion channels, and transporters.
Antibodies selected to recognize native antigens—ensuring compatibility with flow cytometry, immunofluorescence, live-cell imaging, and cell-based assays.
Every VeRSaMAb® Is Extensively Validated, Recombinant, and Specific to Your Target
Validated for performance in your application, recombinant for long-term use, and specific only to your target, ready for your assays and animal models.
Our MAbs Are Pan-Reactive to Bridge Animal and Human Models
Designed for cross-species utility, these antibodies support seamless progression from preclinical models to human systems.
- Validate Across Species: Assess target relevance in rodents, NHPs, and other mammalian models. Get mAbs against targets for any mammalian species: cynomolgus, rat, rabbit, ferret, pig, bat, guinea pig, and more
- One mAb for Animal and Human Models: Confirm function and localization in human cells and tissues with the same mAb
Project Workflow
Built on Integral Molecular’s therapeutic discovery platform
Backed by 20+ years of antibody discovery expertise, we deliver only the highest-quality reagent antibodies—using a unique process designed for superior performance.
- Access Conserved Targets: We immunize chickens, a divergent host, to generate mAbs against conserved mammalian epitopes, enabling pan-reactivity
- High-Throughput, Native-Antigen Discovery: mRNA immunization with Lipoparticle boosts presents native antigens to drive antibody generation against conformational epitopes
- Validated to Perform: Every mAb undergoes specificity screening on the Membrane Proteome Array™ (MPA) and extensive cross-assay validation
Contact Us to Get a Quote and Start a Project